首页 > 市场调查报告书 > 製药

消化器孤儿药

市场调查报告书

商品编码

1830994

克罗恩病治疗市场

Crohn's Disease Therapeutics Market

出版日期: 2025年09月24日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

2024 年克隆氏症治疗市场价值为 102.3 亿美元，预计到 2031 年将达到 133.3 亿美元，2025 年至 2031 年的复合年增长率预计为 4.1%。

市场洞察与分析师观点：克隆氏症是一种慢性发炎性疾病，主要影响胃肠道，尤其是迴肠末端和结肠起始部。此病以消化道内壁发炎为特征，导致腹部不适、腹泻和营养不良等症状。克罗恩病治疗市场的扩张很大程度源自于西方国家（尤其是美国）克隆氏症发病率的上升。此外，企业为维持市场竞争力所采取的策略性措施也推动着市场成长。在预测期内，先进医疗器材的采用率显着上升，预计将为克罗恩病治疗市场带来新的趋势。

成长动力与挑战：克隆氏症被归类为肠躁症，这是一种尚无明确治癒方法的慢性发炎性肠道疾病。此疾病的确切病因尚不清楚，但主要归因于肠道对药物、毒素、感染和肠道微生物等各种因素产生的不适当免疫反应，尤其是在有遗传易感性的人群中。根据美国国家医学图书馆的数据，克隆氏症 (CD) 在西方已开发国家更为常见，尤其是在北美、北欧和纽西兰。此病通常发生在 15 至 30 岁和 40 至 60 岁之间，在城市地区发病率更高。北欧血统和犹太血统的人群发生率尤其高，约为千分之 3.2。然而，最近的研究表明，亚洲、非洲和澳大拉西亚的发病率显着上升，这可能是由于这些地区的快速工业化。因此，这些地区克罗恩病的惊人盛行率正在推动克罗恩病治疗市场的成长。

根据美国国立卫生研究院报告，克罗恩病造成了巨大的经济负担，在欧洲，每位患者每年的直接医疗费用平均约为3500美元。每10万人中约有322人受此病影响，但各国的盛行率差异很大。超过一半的克隆氏症患者可能未确诊，或表现出与其他消化系统疾病相似的症状。此病在女性中较为常见，每1名男性患者对应3名女性。

专注于开发肠躁症治疗方法的製药公司正在积极进行宣传活动，旨在透过向大众普及症状、诊断和治疗方案，有效管理此综合征。 2018年，艾尔建公司 (Allergan PLC) 与 Ironwood 合作推出了一个互动式数位目的地平台，旨在帮助个人自我学习并采取行动应对消化系统疾病。因此，肠躁症盛行率的上升是克隆氏症治疗市场成长的关键驱动力。

策略洞察报告细分和范围：克隆氏症治疗市场分析涵盖多个细分领域，包括药物类型、配销通路和地理。依药物类别，市场分为抗发炎药、免疫系统抑制剂、抗生素、生物製剂、止泻药和止痛药。生物製剂领域在2023年占据最大市场份额，而抗发炎药领域预计将在2023年至2031年期间实现最高复合年增长率。

就终端用户而言，市场细分为医院药房、临床药房和线上平台。 2023年，医院药局占据了克隆氏症治疗市场的最大份额。报告涵盖以下地区的克隆氏症治疗市场：北美（美国、加拿大和墨西哥）、欧洲（西班牙、英国、德国、法国、义大利和欧洲其他地区）、亚太地区（韩国、中国、日本、印度、澳洲和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋和中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲（巴西、阿根廷和南美洲和其他地区）。

区域分析：北美是全球克隆氏症治疗市场成长的主要贡献者。预计亚太地区在2023年至2031年期间的复合年增长率最高。北美市场的成长动力包括：慢性病盛行率的上升、技术进步和创新医疗产品的普及、老龄人口的成长，以及参与新产品和现有产品开发的关键市场参与者的出现。 2023年，美国占据了北美克隆氏症治疗市场的最大份额。

克罗恩病治疗市场报告范围：产业发展与未来机会：克隆氏症治疗市场的预测是基于各种二手和一手研究成果，包括主要公司出版物、协会资料和资料库。根据公司新闻稿，克罗恩病治疗市场主要参与者的重大进展包括：

2023 年，美国食品药物管理局 (FDA) 批准了 Rinvoq (upadacitinib)，这是第一种用于治疗中度至重度克隆氏症的口服药物，适用于对 TNF 阻断药物候选物反应不足的成年患者。 2022 年，FDA 批准 Skyrizi 用于治疗中度至重度活动性克隆氏症成年患者。 2021 年，艾伯维公司宣布启动 risankizumab 的 3 期临床试验，risankizumab 是一种针对白介素 23 (IL-23) 通路的人源化单株抗体，旨在评估其对中度至重度克隆氏症患者的疗效和安全性。 2021 年，武田药品工业株式会社启动了口服化合物 TAK-721（趋化因子受体 CXCR3 的选择性拮抗剂）的 3 期试验，以评估其对中度至重度克隆氏症。竞争格局和主要公司：克罗恩病治疗市场的主要参与者包括 Abbvie, Inc.；强生私人有限公司；葛兰素史克公司；默克公司；诺华公司；新基公司；基因泰克；辉瑞公司；雀巢健康科学；以及勃林格殷格翰有限公司。此外，还分析了其他几家公司，以提供对市场及其生态系统的全面概述。这些公司专注于地理扩张和新产品发布，以满足全球消费者日益增长的需求，并透过专业产品组合拓宽其产品供应。他们的国际影响力使他们能够满足庞大的客户群，从而促进市场成长。

Market Insights and Analyst View:Crohn's disease is a chronic inflammatory disorder that mainly impacts the gastrointestinal tract, particularly the terminal ileum and the beginning of the colon. This condition is marked by inflammation of the digestive tract lining, resulting in symptoms such as abdominal discomfort, diarrhea, and malnutrition. The expansion of the Crohn's disease therapeutics market is largely due to the rising incidence of the disease in Western nations, especially in the US. Furthermore, strategic initiatives by companies to maintain competitiveness in the market are driving growth. A notable rise in the adoption of advanced medical devices is expected to introduce new trends in the Crohn's disease therapeutics market during the forecast period.

Growth Drivers and Challenges:Crohn's disease is classified as an irritable bowel syndrome, a chronic inflammatory bowel disorder without a definitive cure. The precise cause of this condition remains unclear, but it is primarily attributed to an inappropriate immune response in the bowel to various factors such as drugs, toxins, infections, and intestinal microbes, particularly in genetically predisposed individuals. According to the National Library of Medicine, Crohn's disease (CD) is more prevalent in developed Western countries, notably in North America, northern Europe, and New Zealand. The onset of the disease typically occurs in individuals aged 15 to 30 and 40 to 60 years, with a higher prevalence in urban settings. The incidence rate is particularly high among individuals of northern European descent and Jewish ancestry, at approximately 3.2 per 1,000. However, recent research indicates a significant rise in incidence in Asia, Africa, and Australasia, likely due to rapid industrialization in these regions. Consequently, the alarming prevalence of Crohn's disease in these areas is propelling the growth of the Crohn's disease therapeutics market.

As reported by the National Institute of Health, Crohn's disease imposes a considerable economic burden, with direct healthcare costs averaging around US$ 3,500 per patient annually in Europe. The disease affects roughly 322 individuals per 100,000, although prevalence rates can differ significantly between countries. More than half of Crohn's disease patients may remain undiagnosed or exhibit symptoms similar to other digestive disorders. The condition is more frequently observed in women, with a ratio of three women affected for every man.

Pharmaceutical companies focused on developing treatments for irritable bowel syndrome are actively implementing awareness initiatives aimed at effectively managing this syndrome by educating the public about symptoms, diagnosis, and treatment options. In 2018, Allergan PLC and Ironwood collaborated to launch an Interactive Digital Destination platform designed to empower individuals to educate themselves and take action against digestive disorders. Thus, the increasing prevalence of irritable bowel syndrome is a key driver of growth in the Crohn's disease therapeutics market.

Strategic Insights

Report Segmentation and Scope:The analysis of the Crohn's disease therapeutics market has been conducted by examining various segments, including drug type, distribution channel, and geography. By drug class, the market is categorized into anti-inflammatory drugs, immune system suppressors, antibiotics, biologics, anti-diarrheal medications, and pain relievers. The biologics segment held the largest market share in 2023, while the anti-inflammatory drugs segment is projected to achieve the highest CAGR from 2023 to 2031.

In terms of end users, the market is segmented into hospital pharmacies, clinical pharmacies, and online platforms. The hospital pharmacy segment represented the largest share of the Crohn's disease therapeutics market in 2023. Geographically, the report covers the Crohn's disease therapeutics market in North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, Japan, India, Australia, and the Rest of Asia Pacific), the Middle East & Africa (South Africa, Saudi Arabia, UAE, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Regional Analysis:North America is the leading contributor to the global growth of the Crohn's disease therapeutics market. The Asia Pacific region is expected to exhibit the highest CAGR during the period from 2023 to 2031. The market growth in North America is driven by the increasing prevalence of chronic diseases, advancements in technology and access to innovative medical products, a growing elderly population, and the presence of key market players engaged in both new and existing product development. In 2023, the US accounted for the largest share of the Crohn's disease therapeutics market in North America.

Crohns Disease Therapeutics Market Report Scope

Industry Developments and Future Opportunities:The forecast for the Crohn's disease therapeutics market is based on a combination of various secondary and primary research findings, including key company publications, association data, and databases. According to company press releases, significant developments by major players in the Crohn's disease therapeutics market include:

In 2023, the US Food and Drug Administration (FDA) approved Rinvoq (upadacitinib), the first oral pill for treating moderate-to-severe Crohn's disease, intended for adult patients who have not responded adequately to TNF-blocking drug candidates.

In 2022, the FDA granted approval for Skyrizi for the treatment of adults with moderate-to-severe active cases of Crohn's disease.

In 2021, AbbVie Inc. announced the start of a Phase 3 trial for risankizumab, a humanized monoclonal antibody targeting the interleukin-23 (IL-23) pathway, aimed at assessing its efficacy and safety in patients with moderate-to-severe Crohn's disease.

In 2021, Takeda Pharmaceutical Company Limited initiated a Phase 3 trial for the oral compound TAK-721, a selective antagonist of the chemokine receptor CXCR3, to evaluate its efficacy and safety in patients with moderate-to-severe Crohn's disease.

Competitive Landscape and Key Companies:Key players in the Crohn's disease therapeutics market include Abbvie, Inc.; Johnson and Johnson Private Limited; GlaxoSmithKline Plc; Merck and Co., Inc.; Novartis Ag; Celgene Corporation; Genentech; Pfizer Inc.; Nestle Health Science; and Boehringer Ingelheim GmbH. Additionally, several other companies have been analyzed to provide a comprehensive overview of the market and its ecosystem. These companies are focusing on geographic expansion and new product launches to meet the increasing demand from consumers globally and to broaden their product offerings with specialized portfolios. Their international presence enables them to cater to a large customer base, thereby facilitating market growth.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Crohn’s Disease Therapeutics Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Crohn’s Disease Therapeutics Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Crohn’s Disease Therapeutics Market - Global Market Analysis

6.1 Crohn’s Disease Therapeutics - Global Market Overview
6.2 Crohn’s Disease Therapeutics - Global Market and Forecast to 2031

7. Crohn’s Disease Therapeutics Market - Revenue Analysis (USD Million) - By Drug Class, 2021-2031

7.1 Overview
7.2 Anti-inflammatory Drugs
7.3 Immune System Suppressors
7.4 Antibiotics
7.5 Biologics
7.6 Anti-diarrheal
7.7 Pain Relievers

8. Crohn’s Disease Therapeutics Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

8.1 Overview
8.2 Hospital Pharmacy
8.3 Retail Pharmacy
8.4 Online Pharmacy

9. Crohn’s Disease Therapeutics Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

9.1 North America
- 9.1.1 North America Crohn’s Disease Therapeutics Market Overview
- 9.1.2 North America Crohn’s Disease Therapeutics Market Revenue and Forecasts to 2031
- 9.1.3 North America Crohn’s Disease Therapeutics Market Revenue and Forecasts and Analysis - By Drug Class
- 9.1.4 North America Crohn’s Disease Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel
- 9.1.5 North America Crohn’s Disease Therapeutics Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Crohn’s Disease Therapeutics Market
    - 9.1.5.1.1 United States Crohn’s Disease Therapeutics Market, by Drug Class
    - 9.1.5.1.2 United States Crohn’s Disease Therapeutics Market, by Distribution Channel
  - 9.1.5.2 Canada Crohn’s Disease Therapeutics Market
    - 9.1.5.2.1 Canada Crohn’s Disease Therapeutics Market, by Drug Class
    - 9.1.5.2.2 Canada Crohn’s Disease Therapeutics Market, by Distribution Channel
  - 9.1.5.3 Mexico Crohn’s Disease Therapeutics Market
    - 9.1.5.3.1 Mexico Crohn’s Disease Therapeutics Market, by Drug Class
    - 9.1.5.3.2 Mexico Crohn’s Disease Therapeutics Market, by Distribution Channel
9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Crohn’s Disease Therapeutics Market - Key Company Profiles

12.1 Abbvie, Inc.
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Johnson and Johnson Private Limited
12.3 GlaxoSmithKline plc
12.4 Merck and CO., Inc.
12.5 Novartis AG.
12.6 Celgene Corporation
12.7 Genetech
12.8 Pfizer Inc.
12.9 Nestl
12.10 Boehringer Ingelheim GmbH

13. Appendix

13.1 Glossary
13.2 About The Insight Partners
13.3 Market Intelligence Cloud

02-2729-4219

+886-2-2729-4219

License/价格

克罗恩病治疗市场

Crohn's Disease Therapeutics Market

目录

第一章：简介

第二章：执行摘要

第三章：研究方法

第四章：克隆氏症治疗市场格局

第五章：克隆氏症治疗市场－关键市场动态

第六章：克隆氏症治疗市场 - 全球市场分析

第七章：克隆氏症治疗市场 - 收入分析 - 按药物类别，2021-2031 年

第 8 章：克隆氏症治疗市场 - 收入分析 - 按配销通路，2021-2031 年

第九章：克隆氏症治疗市场－收入分析，2021-2031－地理分析

第十章：产业格局

第 11 章：竞争格局

第 12 章：克隆氏症治疗市场 - 关键公司简介

第 13 章：附录

Table Of Contents